Multimodal therapy successfully treats methemoglobinemia caused by emamectin benzoate and indoxacarb poisoning: a case report.

The combination of emamectin benzoate and indoxacarb can lead to severe poisoning, resulting in a range of neurological and hematological symptoms. Neurological symptoms may include confusion, dyspnea, and limb convulsions, which can be distressing and potentially life-threatening. These symptoms are indicative of the body's response to the toxic effects of the poisoning, which can disrupt normal neurological function. In addition to neurological symptoms, methemoglobinemia may also occur, characterized by cyanosis, which is a bluish discoloration of the skin and mucous membranes due to inadequate oxygen delivery to tissues. Treatment of emamectin benzoate poisoning typically involves a multi-faceted approach to alleviate symptoms and prevent organ damage. Naloxone can be used to counteract neurological symptoms, providing relief from confusion, dyspnea, and convulsions. High-dose vitamin C and low-concentration methylene blue can also be administered to reduce methemoglobin (MetHb) levels, which can help to improve hypoxic symptoms and prevent further tissue damage. Furthermore, hemoperfusion and continuous renal replacement therapy (CRRT) can be employed to rapidly remove exogenous and endogenous toxins from the blood, protecting against organ damage to the heart, liver, and kidneys. By utilizing these treatment strategies, healthcare professionals can effectively manage emamectin benzoate poisoning and mitigate its potentially severe consequences. Prompt and aggressive treatment is essential to prevent long-term damage and improve patient outcomes. Link: https://pubmed.ncbi.nlm.nih.gov/40188036/